Methionine aminopeptidases and angiogenesis

Area of Science:

• Biochemistry
• Molecular Biology
• Enzymology

Background:

• Methionine aminopeptidase (MetAP) enzymes are essential for protein synthesis, catalyzing the removal of the N-terminal methionine residue.
• Prokaryotes possess a single MetAP gene, whereas eukaryotes have two distinct isoforms, MetAP1 and MetAP2.
• MetAP enzymes are metalloenzymes that cleave substrates with specific penultimate amino acid residues, including glycine, alanine, serine, threonine, proline, cysteine, and valine.

Purpose of the Study:

• To investigate the function and inhibition of methionine aminopeptidase 2 (MetAP2).
• To understand the mechanism of action of fumagillin-related anti-angiogenic drugs targeting MetAP2.
• To explore the role of MetAP2 in endothelial and cancer cell proliferation.

Main Methods:

• Enzyme kinetics assays to characterize MetAP activity.
• Covalent modification studies to assess drug-target interactions.
• Cell-based assays to evaluate effects on cell-cycle progression and mitogenic activity.

Main Results:

• MetAP2, a eukaryotic isoform, exhibits unique non-proteolytic functions.
• Anti-angiogenic drugs related to fumagillin covalently modify and inhibit MetAP2 protease activity.
• Inhibition of MetAP2 blocks cell-cycle progression in endothelial and certain cancer cells.

Conclusions:

• MetAP2 is a validated target for anti-angiogenic therapies.
• Drug-induced inhibition of MetAP2 impacts cellular proliferation pathways.
• Further research is needed to elucidate the precise role of MetAP2 in cell mitogenesis.